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Abstract
Introduction 
Despite years of declining smoking prevalence, tobacco use is still the leading preventable contributor to illness and 
death in the United States, and the effect of past tobacco-use control efforts has not fully translated into improvements 
in health outcomes. The objective of this study was to use a life course model with multiple competing causes of death 
to elucidate the ongoing benefits of tobacco-use control efforts on US death rates.
Methods 
We used a continuous-time life course simulation model for the US population. We modeled smoking initiation and 
cessation and 20 leading causes of death as competing risks over the life span, with the risk of death for each cause 
dependent on past and current smoking status. Risk parameters were estimated using data from the National Health 
Interview Survey that were linked to follow-up mortality data.
Results 
Up to 14% (9% for men, 14% for women) of the total gain in life expectancy since 1960 was due to tobacco-use control 
efforts. Past efforts are expected to further increase life expectancy by 0.9 years for women and 1.3 years for men. 
Additional reduction in smoking prevalence may eventually yield an average 3.4-year increase in life expectancy in the 
United States. Coronary heart disease is expected to increase as a share of total deaths.
Conclusions 
A dynamic individual-level model with multiple causes of death supports assessment of the delayed benefits of 
improved tobacco-use control efforts. We show that past smoking reduction efforts will translate into further increases 
in life expectancy in the coming years. Smoking will remain a major contributor to preventable illness and death, 
worthy of continued interventions.
Introduction
Despite significant reductions in smoking prevalence nationally and changes in social norms surrounding tobacco use, 
tobacco use persists as the leading cause of preventable illness and death in the United States (1,2). From 2000 
through 2004, one-fifth (45 million) of US adults smoked, resulting in an estimated 443,000 premature deaths and 
$193 billion in direct health care expenditures and productivity losses each year (1). Cigarette smoking is associated 
with or causally linked to myriad health conditions, including cardiovascular diseases; cancers of the lung, oral, and 
nasal cavities and of the esophagus, larynx, pancreas, kidney, and bladder; chronic obstructive pulmonary disease 
(COPD); and infertility, preterm birth, and low birth weight (3-6). In the United States, smoking annually causes more 
than 30% of all cancer deaths and more than 80% of lung cancer deaths (1,7).
Tobacco use control and prevention strategies (ie, education; comprehensive smoke-free policies; taxation of tobacco 
products; evidence-based, culturally targeted cessation approaches; and regulations on advertising, targeting, and 
promotion by tobacco companies) have successfully reduced the age-adjusted smoking prevalence rate among adults 
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aged 18 or older by more than half, from 42.4% in 1965 to 19.3% in 2010 (8,9). Although the reductions in smoking 
prevalence that occurred over the last several decades have led to a substantial reduction in deaths from coronary heart 
disease attributed to smoking (10), lung cancer deaths have declined more slowly (7,11).
Health forecasting models have become more sophisticated with advances in computer technology, the increased 
availability of survey data, an improved understanding of the long-term consequences of lifestyle behaviors, and more 
complex concepts that are translated into models, reflecting a better understanding of interactions and disease 
processes (12). Smoking lends itself well to dynamic modeling because of the long delay between smoking and the 
manifestation of disease (eg, lung cancer), consistent data collected over many decades, and the unambiguous effect of 
smoking on multiple health problems.
Smoking-related health forecasts have been used to inform tobacco-use control strategies for different target 
populations (13) by enhancing understanding of the potential effect of specific policies and interventions on smoking 
rates (14). These models can predict short- and long-term changes in illness, death, life expectancy, quality-adjusted 
life years, female fertility, and health-care expenditures among smokers and the population overall (13,15-17). Full 
effects of smoking cessation can require up to 50 years to measure in individuals. Because cessation efforts translate 
slowly into declining smoking prevalence, it may take up to 100 years to see the full population effect of cessation 
efforts (14). This lag or delayed timing of benefits is rarely considered in models that estimate the magnitude of effect 
of smoking on outcomes.
Because morbidity and cause-specific mortality associated with smoking are affected by competing causes of death, a 
clearer picture of the effect of smoking on longevity would capture competing disease and injury causes of death and 
changes in competing risk factors for smoking-related diseases. Recent work has demonstrated that competing risks 
can be modeled to estimate the joint effect of smoking and obesity, the leading preventable causes of illness and death, 
on life expectancy and quality of life over a 15-year span (18). Although some models have examined the effect of 
smoking on cause-specific mortality (15), to our knowledge, no model has accounted for competing causes of death.
We addressed this gap by using the University of California, Los Angeles (UCLA) Health Forecasting Tool (www.health
-forecasting.org) to estimate the effect of smoking on cause-specific mortality in the United States while accounting for 
competing causes of mortality. We estimated the life expectancy gains in the United States under various smoking 
scenarios. Life expectancy was used to standardize and interpret the magnitude of interventions on health outcomes 
(19,20).
The objective of this study was to use the UCLA Health Forecasting Tool to analyze the effect on US death rates of 
antismoking efforts and predict the nature and magnitude of future benefits.
Methods
Modeling framework
The simulation model is based on a dynamic and continuous-time framework previously developed for the UCLA 
Health Forecasting Model (12,21,22). Continuous-time modeling reduces the complexity of simulating multiple 
processes with many events that otherwise would explode the number of possible state transitions in a discrete-time 
model. The simulation framework provides an algorithm to generate individual lifetime histories starting at birth and 
using probabilities to determine which events happen during the life course. Smoking behavior is simulated by using 
initiation and cessation rates conditional on smoking status and age. Time since cessation is implicitly updated as the 
lifetime history is simulated. Mortality hazards are updated when age and smoking status change, including changes in 
the time since cessation.
Smoking rates
We estimated smoking initiation and cessation rates using sequential cohorts from the National Health Interview 
Survey (NHIS). Initiation is modeled through young adulthood with a constant initiation rate through age 24, after 
which initiation is considered negligible (23). We estimated cumulative initiation through age 24 using the “Have you 
ever smoked” response on the NHIS survey and cessation using the change in prevalence of current smokers over a 5-
year period to obtain the cessation rate of successful quitters. We estimated cessation rates for different age groups; 
the age cutoffs were selected after visual inspection of the smoothed cessation rates over the life span. We assumed 
negligible relapse after 5 years of smoking abstention. We calibrated initiation and cessation rates by using the 
simulation model to account for the decline in smoking prevalence from excess mortality among smokers. This 
approach yielded cumulative rates of initiation of 35% among women and 39% among men for the 1980 birth cohort 
(24-year-olds in 2004), with annual cessation rates of 4.2%, 3.1%, 2.5%, and 4.5% for women aged 15 to 27, 28 to 32, 
33 to 47, and 48 or older, respectively, and 4.0%, 2.8%, 2.1%, and 6.0% for men aged 15 to 27, 28 to 32, 33 to 47, and 
48 or older, respectively. These rates are consistent with observed rates reported elsewhere (24-27). The increase in 
cessation rates as age increases may be driven by health events, such as the onset of heart disease, of the individual or 
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friends and relatives later in life (24,28,29). The smoking prevalence and time since last smoked, as generated by the 
model, were subsequently validated against the observed rates using NHIS data.
Population and causes of death
We chose to simulate a representation of the 2004 US population, which gave us access to a robust data set that 
allowed estimating excess mortality related to tobacco use linked to follow-up data on cause-specific mortality. We 
created a synthetic population based on 2004 population and mortality data from the National Center for Health 
Statistics (NCHS) (30) and obtained cause-specific mortality rates for 2004 from the National Vital Statistics System. 
NCHS provides recodes for 39, 113, 130, and 358 selected causes of death, with varying degrees of specificity (31). We 
used the 39-cause list to identify the top 20 causes of death after excluding 4 nonspecific causes: “Other malignant 
neoplasms,” “Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified,” “All other 
diseases (Residual),” and “All other external causes.”
We estimated the parameters of our analysis by pooling health behavior data from NHIS for 1997 through 2004 and 
linked these with follow-up data on cause-specific mortality through the end of 2006 (32). Data for relative risks of 
smoking on cause-specific mortality are available for select causes and populations (33) but not for each of the 20 
leading causes of death separately for men and women. Therefore, we estimated a Cox proportional hazards model for 
each cause of death to obtain relative risk parameters of smoking (never, current, former [0–4 y, 5–9 y, 10–19 y, or 
≥20 y since quit]) on cause-specific mortality. The estimates were stratified by sex, and the baseline hazards were 
stratified by age (5-year age categories). Relative risk estimates were adjusted for race/ethnicity (6 categories), 
education (less than high school, high school diploma, more than high school), income (<100%, 100%–400%, >400% 
of the federal poverty level), body mass index (BMI, continuous), physical activity (metabolic equivalent time, 
continuous), and alcohol consumption (no alcohol, 0–2 drinks/d, >2 drinks/d).
Simulation scenarios
We simulated 2 sets of scenarios. The first set of scenarios estimated smoking attributable deaths for the 2004 
population and validated the relative risk of smoking on all-cause mortality by comparing our estimates with other 
studies. To estimate smoking-attributable deaths, we ran the simulation model for a 2004 reference scenario, applying 
2004 smoking rates to 40 million simulated individuals reflecting the 2004 population. Next, we ran the 
counterfactual scenario with all relative risks of smoking on mortality set to 1, assuming that smoking has no effect on 
mortality. We compared our estimates of smoking-attributable deaths with estimates from the Centers for Disease 
Control and Prevention (CDC) (1) to validate our model.
The second set of scenarios estimated the effect of past, current, and future changes in initiation and cessation rates 
using a cohort analysis. We used 2004 mortality rates throughout the life course, similar to life table calculations, and 
compared mortality and life expectancy in a birth cohort followed from birth to death. We held initiation and cessation 
rates fixed at levels specified in each scenario. We simulated cohorts of 4 million individuals in each scenario, by using 
different assumptions about smoking initiation and cessation rates to estimate the timing of changes in smoking 
initiation and cessation on mortality (Box). Comparing scenarios 3 and 6, for example, yields the difference in 
mortality, life expectancy, and distribution of causes of death between never smokers and always smokers (if viewed 
from the individual perspective, the probabilistic outcome of death with continuous lifelong smoking vs never 
smoking). We compared age-adjusted mortality rates and life expectancy with the reference scenario to estimate past 
and potential future gains from tobacco-use control efforts.
Timing of benefits
Smoking-related deaths occur among people of all ages. 
Gains in life expectancy occur across a significant 
portion of the life span and not just later in life. We 
estimated expected gains at the individual level for men 
and women by repeated simulation of individuals 
quitting smoking at various ages and comparing the 
total remaining life years to those of lifetime smokers. 
These individual-level gains were aggregated over a 
simulated cohort for each scenario, yielding gains in life 
years across the lifespan for the entire cohort. We 
calculated gains in life years relative to scenario 4, 
which used initiation and cessation rates from the 
1950s, to calculate past and future gains from 
reductions in smoking. To calculate gains in life years 
for the 2004 population, we applied age-specific 2004 
mortality rates to a standard cohort, similar to life 
expectancy calculations.
Box. Smoking Initiation and Cessation 
Scenarios
Scenario Rationale
2004 Analysis
1. Reference 
calibrated to 2004
Used as a reference to 
compare alternative 
scenarios
2. Counterfactual 
where smoking has 
no effect on 
mortality
Used to calculate smoking 
attributable deaths by 
comparing to the reference 
scenario
Cohort Analysis
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Results
Model validation
We estimated that 18.9% of adult women and 23.1% of 
adult men were current smokers in 2004, as compared 
with observed rates of 18.5% and 23.4%, respectively 
(34). We estimated smoking-attributable deaths at 
420,000 in 2004 (Table 1), which is comparable to 
CDC estimates of 443,000 deaths annually from 2000 
through 2004 (1). We found that 15% of all deaths 
among women and 20% of all deaths among men were 
attributable to smoking. Most of the deaths avoided 
derive from a reduction in cancer of the trachea, 
bronchus, or lung (27%) and chronic lower respiratory 
diseases (21%). The data presented in Table 2, 
simulated smoking rates, life expectancy, and mortality 
by cause of death for 2004, are a reference to compare 
the 4 scenarios. In 2004, nearly half of adult men and 
approximately 37% of adult women had smoked at 
some point in their adult life; life expectancy was 75.1 
years for men and 80.2 years for women.
Life expectancy benefits
Table 3 summarizes estimates of the effect of smoking initiation and cessation on smoking prevalence and mortality 
outcomes for scenarios 3 through 6. Smoking prevalence is age-adjusted to the 2004 US population by sex to facilitate 
comparison of the cohort scenarios with the reference scenario (scenario 1). Initiation and cessation rates in the 1940s 
and 1950s, scenario 4, result in a lifetime smoking prevalence of 33% for women and 48% for men; life expectancy is 
reduced to 79.6 years for women and 73.9 years for men.
Comparing scenario 4 with the reference scenario shows that changes in initiation and cessation rates since 1960 have 
resulted in a life expectancy increase of 0.6 years for women and 1.2 years for men. Moreover, at 2004 initiation and 
cessation rates (scenario 5), an additional 0.9 years for women (life expectancy, 81.1 y) and 1.3 years for men (life 
expectancy, 76.4 y) may be realized in the future, because 2004 initiation and cessation rates will continue to yield 
reductions in current smokers and ever smokers and their related mortality (scenario 5 vs reference). Fully eliminating 
tobacco use in the population (scenario 6) would yield an increase in life expectancy of 1.2 years for women and 1.6 
years for men, or 82.3 and 78.0 years, respectively.
Causes of mortality
Although overall age-adjusted mortality declines with reductions in smoking prevalence, trends vary by disease. 
Reductions in smoking prevalence lead to a substantial reduction in deaths from lung cancer and COPD. However, 
although smoking increases the risk of coronary heart disease, heart disease as a percentage of total deaths is higher 
for never smokers than for always smokers (scenario 3 compared with scenario 6). In fact, the share of total deaths 
held by ischemic heart disease (IHD) has risen and is expected to continue to increase if smoking prevalence declines 
further (Table 3).
Timing of benefits
Longevity gains of quitters relative to lifetime smokers were recorded across the lifespan (Figure 1). Using a cohort of 
10,000 people at birth, we plotted years of life gained across the life span (Figure 2). The life years already gained is the 
difference between the years of life for the 2004 population (reference scenario) and scenario 4. The life years yet to be 
gained if 2004 initiation and cessation rates persist are the difference between scenario 5 and the reference scenario, 
and the life years that may be gained if no one ever smoked is the difference between scenario 6 and scenario 5. The 
area under the curve is equal to the gain in life expectancy (∆LE). Substantial gains have already been realized during 
the life course (life expectancy gain of 0.6 y for women and 1.2 y for men), and additional gains will occur mostly at 
older ages if initiation and cessation rates stay at 2004 levels (additional life expectancy gain of 0.9 y for women and 
1.3 y for men) (Figure 2). The largest gains in years of life across the lifespan may be realized if all individuals in the 
cohort remain never smokers, providing an additional gain in life expectancy of 1.2 years for women and 1.6 years for 
men (scenario 6).
3. 100% initiation 
and 0% cessation for 
all adult men and 
women
Used to generate distribution 
of causes of death for 
“always smokers”
4. 55% initiation for 
women/80% 
initiation for men and 
cessation half of 
2004 rates 
(described in text)
Used to generate distribution 
of causes of death for cohort 
assuming smoking rates 
observed in the 1940–1950s 
before public health action to 
reduce smoking prevalence 
(to estimate the effect of 
antismoking public health 
programs)
5. 2004 initiation and 
cessation rates 
(described in text)
Used to generate distribution 
of causes of death for cohort 
assuming 2004 initiation and 
quit rates
6. 0% initiation Used to generate distribution 
of causes of death for “never 
smokers”
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Figure 1. Expected gain in years of life across the lifespan by age of quitting, relative to a lifetime smoker, by sex. 
After quitting smoking, individuals are more likely to be alive at every age after the quit age. The largest gain is around 
age 80, but gains are smaller for those who quit later in life. [A tabular version of this figure is also available.]
Figure 2. Gains in years of life relative to mid-1900s initiation and cessation rates, by age and sex. Lower initiation 
and cessation rates have yielded additional life years in the population at all ages (area under the curve is the gain in 
life expectancy (∆LE), and additional gains are expected if initiation and cessation rates stay at 2004 levels. [A tabular 
version of this figure is also available.]
Discussion
Our simulation model is a dynamic tool to estimate health effects of various scenarios, taking into account the timing 
of smoking initiation, cessation, and the effect on health outcomes. We can evaluate what may have happened if 
smoking behavior had not changed and estimate what could be attained with further tobacco-use control efforts. We 
found that, as of 2004, reductions in smoking prevalence resulted in life expectancy gains equal to nearly 9% of the 
total gain in female life expectancy and 14% of the total gain in male life expectancy from 1960 to 2004. However, at 
current initiation and cessation rates, additional life expectancy gains approximately equal to the total observed gains 
from 1995 through 2004 are expected (35). The magnitude of these gains and the potential for additional gains if 
smoking rates can be reduced further underscore the importance of continuing tobacco-use control efforts.
The simulation also helps assess the distribution of gains across the lifespan and how the fractions of mortality 
attributable to various diseases may change as smoking prevalence is reduced. For example, as a share of total deaths, 
IHD is expected to increase, despite a decline in smoking rates and a decline in age-adjusted IHD mortality, reflecting 
a shift in mortality away from lung cancer and COPD to IHD and other causes of death. Causes of death minimally 
Page 5 of 10CDC - Preventing Chronic Disease: Volume 9, 2012: 11_0295
affected by smoking, such as injuries, or occurring primarily at older ages, such as Alzheimer’s disease, will also 
increase their share of total deaths.
We have inherent limitations in our modeling approach. First, our model treats people separately from their 
environment. Therefore, passive smoking and effects of air pollution are ignored. Similarly ignored are 
intergenerational effects, including how smoking by pregnant mothers affects the health and mortality risk of infants 
and how parents who smoke are more likely to have children who eventually initiate smoking. Furthermore, smoking 
intensity was not modeled in the simulation. This exclusion may bias effect estimates if ongoing cessation efforts have 
also changed smoking intensity. However, our estimates of the benefits of reduced smoking initiation and increased 
cessation are likely conservative with the exclusion of passive smoking, intergenerational effects, and decline in 
smoking intensity (8). Moreover, by focusing on smoking-attributable mortality, we omit the quality-of-life benefits 
from reductions in smoking-related morbidity.
Although this study incorporates competing causes of death, it did not include comorbidities and competing behavioral 
risks for illness and death, despite their potential relevance. For example, mental illness is associated with higher 
smoking prevalence and other unhealthy behaviors as well as increased mortality (36,37). Also, obesity differentially 
affects smoking-related diseases (18), and current increases in obesity prevalence are likely to further increase 
cardiovascular mortality relative to lung cancer and COPD mortality.
Our model can help inform future public health campaigns and assist in prioritizing scarce resources. Future work 
should focus on adding additional health risk factors, such as obesity or other morbidities, to better understand how 
reductions in smoking prevalence will reduce and shift the burden of disease. Moreover, expanding the framework to 
include passive smoking and intergenerational effects would better capture the full benefits of reductions in smoking 
prevalence, and stratification by race/ethnicity would provide insight into causes of health disparities.
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Tables 
 
Table 1. Estimated Deaths Avoided in the Absence of Smoking, Causes of 
Death, Simulation Model, 2004 US Population
Cause of Death
Deaths Avoided (in Thousands), n 
(% Reduction)
Age-Adjusted Mortality (per 100,000), n 
(% Total Mortality)
Female Male Female Male
Ischemic heart diseases 25 (15) 41 (17) 103 (18) 172 (21)
Cancer of trachea, 
bronchus, and lung
49 (70) 66 (71) 12 (2) 22 (3)
Chronic lower respiratory 
diseases
47 (72) 40 (66) 10 (2) 18 (2)
All other causes 60 (7) 92 (11) 277 (48) 354 (44)
Total 181 (15) 239 (20) 579 (100) 808 (100)
Table 2. Life Expectancy and Mortality, by Cause of Death, United States, 
2004
Life Expectancy Female Male
Current smokers (adults 
≥18), %
18.9 23.1
Former smokers (adults 
≥18), %
18.2 25.7
Life expectancy, y 80.2 75.1
Cause of Death
Total Deaths (in 
Thousands)
Age-Adjusted (Per 
100,000 Population)
Total Deaths (in 
Thousands)
Age-Adjusted (Per 
100,000 Population)
All 1,222 688 1,193 1,002
Ischemic heart diseases 219 118 236 205
Other heart diseases (no 
CHD)
94 51 75 67
Cancer of trachea, 
bronchus, and lung
70 42 92 73
Cerebrovascular diseases 92 50 59 53
Chronic lower respiratory 
diseases
65 37 61 53
Diabetes mellitus 38 22 36 29
Unspecified accidents and 
adverse effects
28 17 42 32
Alzheimerâ€™s disease 47 24 20 20
Influenza and pneumonia 33 18 27 25
a
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Life Expectancy Female Male
Cancer of colon, rectum, 
and anus
27 16 26 22
Motor vehicle accidents 15 10 31 22
Nephritis, nephrotic 
syndrome, and nephrosis
22 12 21 19
Cancer of breast 41 25 0 0
Intentional self-harm 7 5 26 18
Hypertensive heart 
disease
17 9 15 12
Cancer of pancreas 16 9 16 12
Cancer of prostate NA NA 29 27
Chronic liver disease and 
cirrhosis
9 6 18 13
Cancer of urinary tract 9 5 17 14
Cancer of cervix uteri, 
corpus uteri, and ovary
25 15 NA NA
All other causes 348 198 348 286
Abbreviation: NA, not applicable. 
 Numbers in the table are from model output for 2004 after calibration with vital statistics data from the National Center 
for Health Statistics.
 
Table 3. Life Expectancy, Age-Adjusted Mortality, and Causes of Deaths in a 
Cohort Using Different Smoking Rates, United States
Cause of Death/Life 
Expectancy/Age-Adjusted 
Mortality
Scenario 3: All 
Smoking
Scenario 4: 1940s-
1950s Rates
Scenario 5: 
2004 Rates
Scenario 6: No 
Smoking
Female Male Female Male Female Male Female Male
Current adult smokers,  % 100 100 32.9 47.9 14.4 16.4 0 0
Former adult smokers,  % 0 0 20.2 30.3 19.2 21.2 0 0
Life expectancy, y 74.9 70.1 79.6 73.9 81.1 76.4 82.3 78.0
Age-adjusted mortality 1,176 1,644 725 1,080 646 896 579 805
Distribution of Deaths by Cause, %
Ischemic heart diseases 17.9 21.8 18.9 21.0 19.5 21.9 20.5 22.8
Other heart diseases (no CHD) 4.4 6.1 7.9 6.6 8.9 7.5 9.9 8.0
Cancer of trachea, bronchus, and 
lung
14.4 14.7 6.1 8.7 3.5 4.7 1.8 2.6
Cerebrovascular diseases 7.6 3.2 7.8 5.1 8.2 6.3 8.7 7.0
Chronic lower respiratory 
diseases
11.3 10.0 6.2 6.2 4.3 3.9 1.7 2.4
Diabetes mellitus 1.9 1.8 2.9 2.7 3.1 3.2 3.4 3.5
Unspecified accidents and 
adverse effects
3.7 2.9 2.1 2.9 1.9 3.0 1.8 3.0
Alzheimer’s disease 2.0 1.2 4.1 1.9 4.7 2.5 5.3 2.8
Influenza and pneumonia 2.3 2.8 2.9 2.7 3.1 2.9 3.4 3.0
a
a
b
b
c
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Cause of Death/Life 
Expectancy/Age-Adjusted 
Mortality
Scenario 3: All 
Smoking
Scenario 4: 1940s-
1950s Rates
Scenario 5: 
2004 Rates
Scenario 6: No 
Smoking
Female Male Female Male Female Male Female Male
Cancer of colon, rectum, and 
anus
1.8 2.1 2.1 2.2 2.1 2.3 2.1 2.5
Motor vehicle accidents 0.8 1.3 0.8 1.6 0.8 1.7 0.8 1.8
Nephritis, nephrotic syndrome, 
and nephrosis
1.1 1.1 1.8 1.8 2.0 2.2 2.1 2.4
Cancer of breast 1.4 0 2.8 0 3.0 0 3.1 0
Intentional self-harm 0.8 1.8 0.4 1.7 0.3 1.3 0.2 1.1
Hypertensive heart disease 0.8 0.7 1.4 1.1 1.6 1.3 1.8 1.4
Cancer of pancreas 1.4 0.8 1.3 1.2 1.2 1.4 1.2 1.5
Cancer of prostate NA 1.6 NA 2.6 NA 3.3 NA 3.7
Chronic liver disease and 
cirrhosis
0.9 1.3 0.6 1.2 0.6 1.0 0.6 1.0
Cancer of urinary tract 0.4 1.5 0.7 1.5 0.7 1.2 0.8 0.9
Cancer of cervix uteri, corpus 
uteri, and ovary
1.3 NA 1.8 NA 1.9 NA 2.0 NA
All other causes 23.0 23.3 27.5 27.4 28.5 28.4 28.9 28.6
Abbreviation: CHD, coronary heart disease; NA, not applicable. 
 Cohorts simulated from birth to death to calculate eventual cause of death for alternative scenarios. 
 Aged ≥18 y, age-adjusted. 
 Per 100,000 2004 population.
 
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. 
Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, 
or the authors’ affiliated institutions. 
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